Hill, K., Giantini-Larsen, A., Hickman, R. A., Holle, B., Alano, T., Doe-Tetteh, S., Bouvier, N., Li, S., Stockfisch, E., Huereca, C., DiNapoli, S., Hertz, C. A., Lee, A., Szalontay, L., Li, B. K., Riviere-Cazaux, C., Burns, T. C., Haque, S., Bale, T., … Miller, A. (2023). METB-05. NON-INVASIVE DIAGNOSIS OF BRAINSTEM GLIOMAS IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT PATIENTS THROUGH CEREBROSPINAL FLUID CELL-FREE DNA SEQUENCING. Neuro-Oncology, 25(Supplement_1), i31–i31. https://doi.org/10.1093/neuonc/noad073.122

Ramirez, A., Jonokuchi, A., Hijiya, N., Gomes, W., Wesley, S., & Kaur, G. (2023). IMMU-19. NIVOLUMAB-INDUCED CNS DEMYELINATION IN A 15-YEAR-OLD WITH CLASSIC HODGKIN LYMPHOMA. Neuro-Oncology, 25(Supplement_1), i53–i53. https://doi.org/10.1093/neuonc/noad073.206

Vize, C. J., Kim, S. K., Matthews, T., Macsai, M., Merrell, R., Hsu, S., Kundu, M. G., Yoon, J., Kennedy, E., Pai, M., Bain, E., Lassman, A. B., & Moazami, G. (2023). A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin. Ophthalmic Research, 1030–1043. Portico. https://doi.org/10.1159/000531142

Shang, E., Nguyen, T. T. T., Westhoff, M.-A., Karpel-Massler, G., & Siegelin, M. D. (2023). Targeting cellular respiration as a therapeutic strategy in glioblastoma. Oncotarget, 14(1), 419–425. https://doi.org/10.18632/oncotarget.28424

Ramkissoon, S. H., Fernandes, H., Lopez-Terrada, D. H., Hameed, M. R., Trembath, D. G., Bridge, J. A., Lindeman, N. I., Souers, R. J., Vasalos, P., Brat, D. J., & Moncur, J. T. (2022). Clinical Laboratory Testing Practices in Diffuse Gliomas Prior to Publication of 2021 World Health Organization Classification of Central Nervous System Tumors. Archives of Pathology & Laboratory Medicine, 147(5), 518–524. https://doi.org/10.5858/arpa.2021-0431-cp

Cocito, C., Martin, B., Giantini-Larsen, A. M., Valcarce-Aspegren, M., Souweidane, M. M., Szalontay, L., Dahmane, N., & Greenfield, J. P. (2023). Leptomeningeal dissemination in pediatric brain tumors. Neoplasia, 39, 100898. https://doi.org/10.1016/j.neo.2023.100898

Migliozzi, S., Oh, Y. T., Hasanain, M., Garofano, L., D’Angelo, F., Najac, R. D., Picca, A., Bielle, F., Di Stefano, A. L., Lerond, J., Sarkaria, J. N., Ceccarelli, M., Sanson, M., Lasorella, A., & Iavarone, A. (2023). Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy. Nature Cancer, 4(2), 181–202. https://doi.org/10.1038/s43018-022-00510-x

Liau, L. M., Ashkan, K., Brem, S., Campian, J. L., Trusheim, J. E., Iwamoto, F. M., Tran, D. D., Ansstas, G., Cobbs, C. S., Heth, J. A., Salacz, M. E., D’Andre, S., Aiken, R. D., Moshel, Y. A., Nam, J. Y., Pillainayagam, C. P., Wagner, S. A., Walter, K. A., Chaudhary, R., … Bosch, M. L. (2023). Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma. JAMA Oncology, 9(1), 112. https://doi.org/10.1001/jamaoncol.2022.5370

Argenziano, M. G., Furnari, J. L., Miller, M. L., Sun, Y., Banu, M. A., Neira, J. A., Snuderl, M., Bruce, J. N., Welch, M., McCormick, P., & Canoll, P. (2022). Thoracic low grade glial neoplasm with concurrent H3 K27M and PTPN11 mutations. Acta Neuropathologica Communications, 10(1). https://doi.org/10.1186/s40478-022-01340-9

Schvartzman, J. M., & Intlekofer, A. M. (2022). D-2HG comes out of its shell: Metabolic effects on the immune environment. Molecular Cell, 82(23), 4407–4409. https://doi.org/10.1016/j.molcel.2022.11.005

Gallitto, M., Savacool, M., Lee, A., Wang, T. J. C., & Sisti, M. B. (2022). Feasibility of fractionated gamma knife radiosurgery in the management of newly diagnosed Glioblastoma. BMC Cancer, 22(1). https://doi.org/10.1186/s12885-022-10162-w

Miller, M. L., Griepp, D. W., Sun, Y., Tamir, S., Farber, R. S., Otten, M. L., & Al‐Dalahmah, O. (2022). A 53‐year‐old woman with a rapidly progressive, non‐enhancing left frontotemporal lesion. Brain Pathology, 33(2). Portico. https://doi.org/10.1111/bpa.13125

Pan, P., Haggiagi, A., & Iwamoto, F. (2022). BIOM-12. PROLONGED RESPONSE TO THIRD-LINE TREATMENT WITH COMBINATION CCNU/TMZ IN AN MGMT METHYLATED IDH-WILDTYPE GLIOBLASTOMA. Neuro-Oncology, 24(Supplement_7), vii6–vii6. https://doi.org/10.1093/neuonc/noac209.022

Minns, H., Padilla, O., Wei, H.-J., Webster-Carrion, A., Tazhibi, M., McQuillan, N., Zhang, X., Yeh, R., Zhang, Z., Szalontay, L., Pavisic, J., Garty, G., Garvin, J., Canoll, P., Vanpouille-Box, C., Menon, V., Olah, M., Rabadan, R., Wu, C.-C., & Gartrell, R. (2022). TMIC-68. EVALUATING FLASH AND CONVENTIONAL DOSE-RATE RADIATION AND IMMUNE RESPONSE WITH SINGLE-CELL SEQUENCING IN DIFFUSE MIDLINE GLIOMA (DMG). Neuro-Oncology, 24(Supplement_7), vii286–vii286. https://doi.org/10.1093/neuonc/noac209.1111

Iwamoto, F., Gondi, V., Butowski, N., Falchook, G., Williams, A., Peters, K. B., Evans, J., Lakhani, N., McKean, M., Symeonides, S., Ellingson, B., Rotolo, J., Capiaux, G., Wiegert, E., Michel, R., Kaesshaefer, S., & Bexon, A. (2022). CTNI-49. EARLY SIGNAL OF ACTIVITY FROM A PHASE 2 STUDY OF ST101, A FIRST-IN-CLASS PEPTIDE ANTAGONIST OF CCAAT/ENHANCER-BINDING PROTEIN Β (C/EBPΒ), IN RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology, 24(Supplement_7), vii83–vii83. https://doi.org/10.1093/neuonc/noac209.314

Ellingson, B., Wen, P. Y., Chang, S., van den Bent, M., Vogelbaum, M., Li, G., Li, S., Kim, J., Youssef, G., Wick, W., Lassman, A., Gilbert, M., de Groot, J., Weller, M., Galanis, E., & Cloughesy, T. (2022). NIMG-42. DURABLE OVERALL RESPONSE RATE (ORR) TARGETS FOR RECURRENT GLIOBLASTOMA (RGBM) CLINICAL TRIALS BASED ON THE HISTORIC ASSOCIATION BETWEEN ORR AND MEDIAN OVERALL SURVIVAL (MOS). Neuro-Oncology, 24(Supplement_7), vii172–vii173. https://doi.org/10.1093/neuonc/noac209.660

Yuen, C., Pan, P., Teasley, D., Miller, M., Sun, Y., Canoll, P., Joanta-Gomez, A., Bargo, A., & Iwamoto, F. (2022). PATH-32. CONCORDANCE FOR CDKN2A/B LOSS AND TERT MUTATION IN WHO 2021 CLASSIFICATION GRADE 3 MENINGIOMAS: A RETROSPECTIVE STUDY. Neuro-Oncology, 24(Supplement_7), vii157–vii157. https://doi.org/10.1093/neuonc/noac209.605

Arrillaga-Romany, I., Lassman, A., McGovern, S., Mueller, S., Nabors, L. B., van den Bent, M., Vogelbaum, M., Allen, J. E., Melemed, A., Tarapore, R., Yang, D., Wen, P. Y., & Cloughesy, T. (2022). RTID-01. ONC108: A RANDOMIZED PHASE 3 STUDY OF ONC201 IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA. Neuro-Oncology, 24(Supplement_7), vii249–vii249. https://doi.org/10.1093/neuonc/noac209.961

Donovan, L., Joanta-Gomez, A., Furnari, J., Mouton, B., & Lassman, A. (2022). QOL-01. RISK FACTORS FOR AND CONSEQUENCES OF PROLONGED DEXAMETHASONE USE IN PATIENTS WITH GLIOBLASTOMA (GBM). Neuro-Oncology, 24(Supplement_7), vii240–vii240. https://doi.org/10.1093/neuonc/noac209.929

Iwamoto, F., Polley, M.-Y., Shaw, E., Buckner, J., Barger, G., Coons, S., Ricci, P., Gilbert, M., Brown, P., Stelzer, K., Rogers, C. L., Suh, J., Schultz, C., Howard, S., Fisher, B., Kim, M., Huang, J., Haddock, M., Won, M., & Mehta, M. (2022). CTNI-16. NRG-RTOG 9802 OBSERVATION ARM - LONG TERM RESULT. Neuro-Oncology, 24(Supplement_7), vii73–vii73. https://doi.org/10.1093/neuonc/noac209.282

Bagley, S., Polley, M.-Y., Kotecha, R., Brem, S., Tolakanahalli, R., Iwamoto, F., Gilbert, M., Won, M., & Mehta, M. (2022). CTIM-21. NRG-BN010: A SAFETY RUN-IN AND PHASE II STUDY EVALUATING THE COMBINATION OF TOCILIZUMAB, ATEZOLIZUMAB, AND FRACTIONATED STEREOTACTIC RADIOTHERAPY IN RECURRENT GLIOBLASTOMA – TRIAL IN PROGRESS. Neuro-Oncology, 24(Supplement_7), vii64–vii64. https://doi.org/10.1093/neuonc/noac209.253

Pan, P., Joanta-Gomez, A., Yuen, C., Donovan, L., Haggiagi, A., Welch, M., Iwamoto, F., & Lassman, A. (2022). NCOG-24. TIME TO FIRST RECURRENCE AND SURVIVAL IN IDH-WILDTYPE GLIOBLASTOMA. Neuro-Oncology, 24(Supplement_7), vii202–vii202. https://doi.org/10.1093/neuonc/noac209.776

Liau, L. M., Ashkan, K., Brem, S., Campian, J., Trusheim, J., Iwamoto, F., Tran, D., Anstass, G., Cobbs, C., Heth, J., Salacz, M., D’Andre, S., Aiken, R., Moshel, Y., Nam, J., Pillainayagam, C., Wagner, S., Walter, K., Chaudary, R., … Bosch, M. (2022). CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL. Neuro-Oncology, 24(Supplement_7), vii66–vii66. https://doi.org/10.1093/neuonc/noac209.259

Oh, M., Hasanain, M., Migliozzi, S., Garofano, L., D’Angelo, F., Stefano, A. L. D., Lerond, J., Sarkaria, J., Ceccarelli, M., Sanson, M., Lasorella, A., & Iavarone, A. (2022). EXTH-21. DEVELOPMENT OF THERAPEUTIC STRATEGIES BY PATHWAY-BASED MULTI-OMICS APPROACH AND MASTER KINASE ANALYSIS IN GLIOBLASTOMA MULTIFORME. Neuro-Oncology, 24(Supplement_7), vii214–vii214. https://doi.org/10.1093/neuonc/noac209.820

Mrugala, M., Shi, W., Iwamoto, F., Lukas, R., Palmer, J., Suh, J., & Glas, M. (2022). INNV-07. TUMOR TREATING FIELDS (TTFIELDS; 200 KHZ) POST-MARKETING SAFETY DATA FROM PATIENTS WITH GLIOBLASTOMA TREATED BETWEEN 2011–2022. Neuro-Oncology, 24(Supplement_7), vii142–vii142. https://doi.org/10.1093/neuonc/noac209.547

Miller, A. M., Szalontay, L., Bouvier, N., Hill, K., Ahmad, H., Rafailov, J., Lee, A. J., Rodriguez-Sanchez, M. I., Yildirim, O., Patel, A., Bale, T. A., Benhamida, J. K., Benayed, R., Arcila, M. E., Donzelli, M., Dunkel, I. J., Gilheeney, S. W., Khakoo, Y., Kramer, K., … Karajannis, M. A. (2022). Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients. Neuro-Oncology, 24(10), 1763–1772. https://doi.org/10.1093/neuonc/noac035

Torrini, C., Nguyen, T. T. T., Shu, C., Mela, A., Humala, N., Mahajan, A., Seeley, E. H., Zhang, G., Westhoff, M.-A., Karpel-Massler, G., Bruce, J. N., Canoll, P., & Siegelin, M. D. (2022). Lactate is an epigenetic metabolite that drives survival in model systems of glioblastoma. Molecular Cell, 82(16), 3061-3076.e6. https://doi.org/10.1016/j.molcel.2022.06.030

Arrillaga-Romany, I., Kurz, S., Tarapore, R., Lu, G., Sumrall, A., Butowski, N., Harrison, R., DeGroot, J., Chi, A., Shonka, N., Umemura, Y., Odia, Y., Mehta, M., Nghiemphu, P., Cloughesy, T., Taylor, L., Graber, J., Kilburn, L., Dixit, K., … Wen, P. (2022). SYST-14 CLINICAL EFFICACY OF ONC201 IN RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA (DMG) PATIENTS. Neuro-Oncology Advances, 4(Supplement_1), i24–i24. https://doi.org/10.1093/noajnl/vdac078.093

Rubens, J. A., Erker, C., Lindsay, H., Ho, B., Li, B., Bouffet, E., Cohen, A., Eberhart, C., Ertl-Wagner, B., Mahajan, A., Zacharoulis, S., Huang, A., & Packer, R. (2022). Infantile suprasellar tumor diagnosed as a pineoblastoma RB1 subgroup and treatment challenges: A pediatric SNO Molecular Tumor Board. Neuro-Oncology Advances, 4(1). https://doi.org/10.1093/noajnl/vdac092

Jairam, V., Park, H. S., Yu, J. B., Bindra, R. S., Contessa, J. N., & Jethwa, K. R. (2022). Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole Brain Radiation Therapy. Advances in Radiation Oncology, 7(4), 100949. https://doi.org/10.1016/j.adro.2022.100949

Al-Dalahmah, O. A., Wang, L., Hsiao, S. J., Lin, C.-C., Mansukhani, M. M., Canoll, P., Bruce, J. N., & Zanazzi, G. (2022). Pineal region ganglioglioma: A neoplasm with a bimodal age distribution. Surgical Neurology International, 13, 245. https://doi.org/10.25259/sni_443_2022

Varn, F. S., Johnson, K. C., Martinek, J., Huse, J. T., Nasrallah, M. P., Wesseling, P., Cooper, L. A. D., Malta, T. M., Wade, T. E., Sabedot, T. S., Brat, D., Gould, P. V., Wöehrer, A., Aldape, K., Ismail, A., Sivajothi, S. K., Barthel, F. P., Kim, H., Kocakavuk, E., … Verhaak, R. GW. (2022). Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell, 185(12), 2184-2199.e16. https://doi.org/10.1016/j.cell.2022.04.038

Fernández, E. C., Wang, J., Griffin, A., Minns, H., Wei, H.-J., Zhang, X., Szalontay, L., Mundi, P., Wu, C.-C., Gartrell, R., Zacharoulis, S., Califano, A., & Pavisic, J. (2022). DIPG-57. A systems biology approach to defining and targeting master regulator dependencies from bulk and single-Cell RNA-seq in diffuse midline glioma (DMG). Neuro-Oncology, 24(Supplement_1), i31–i32. https://doi.org/10.1093/neuonc/noac079.114

McQuillan, N., Tazhibi, M., Wei, H.-J., Pouliopoulos, A., Bendau, E., Carrion, A. W., Berg, A., Kokossis, D., Zhang, X., Zhang, Z., Englander, Z., Yoh, N., Jan, C.-I., Gartrell, R. D., Garvin, J., Szalontay, L., Konofagou, E., Zacharoulis, S., & Wu, C.-C. (2022). MODL-25. Radiation and focused ultrasound–mediated blood–brain barrier opening for DMG: safety and feasibility of combinatorial therapy. Neuro-Oncology, 24(Supplement_1), i174–i174. https://doi.org/10.1093/neuonc/noac079.648

Hill, K., Miller, A. M., Li, B. K., Bouvier, N., Li, S., Alano, T., Doe-Tetteh, S., Huereca, C., DiNapoli, S., Lee, A., Szalontay, L., Riviere-Cazaux, C., Burns, T. C., Haque, S., Bale, T., Benhamida, J., Dogan, S., Vanderbilt, C., Ross, D., … Karajannis, M. (2022). PATH-16. Noninvasive diagnosis of gliomas through CSF cfDNA sequencing in pediatric and adolescent and young adult (AYA) patients. Neuro-Oncology, 24(Supplement_1), i162–i162. https://doi.org/10.1093/neuonc/noac079.600

Minns, H. E., Padilla, O., Wei, H.-J., Webster-Carrion, A., Tazhibi, M., McQuillan, N., Zhang, X., Yeh, R., Zhang, Z., Szalontay, L., Pavisic, J., Garty, G., Garvin, J., Zacharoulis, S., Canoll, P., Vanpouille-Box, C. I., Menon, V., Olah, M., Rabadan, R., … Gartrell, R. D. (2022). DIPG-45. Radiation induces a robust interferon response in Diffuse Midline Glioma (DMG), improving the potential for combination immunotherapy. Neuro-Oncology, 24(Supplement_1), i28–i29. https://doi.org/10.1093/neuonc/noac079.102

Zacharoulis, S., Szalontay, L., CreveCoeur, T., Neira, J., Higgins, D., Englander, Z., Spinazzi, E., Sethi, C., Canoll, P., Garvin, J., Zylber, R., Damment, S., Zamoryakhin, D., Maddocks, A., Feldstein, N., & Bruce, J. (2022). DDEL-07. A Phase I study examining the feasibility of intermittent convection-enhanced delivery (CED) of MTX110 for the treatment of children with newly diagnosed diffuse midline gliomas (DMGs). Neuro-Oncology, 24(Supplement_1), i35–i35. https://doi.org/10.1093/neuonc/noac079.128

Webster Carrion, A., Wei, H.-J., McQuillan, N., Tazhibi, M., Kokossis, D., Berg, X., Minns, H., Zhang, X., Zhang, Z., Wang, J., Fernandez, E. C., Jan, C.-I., Padilla, O., Gartrell, R. D., Becher, O., Jr, J. H. G., Pavisic, J., Szalontay, L., Konofagou, E. E., … Wu, C.-C. (2022). MODL-24. Focused ultrasound-mediated blood-brain barrier opening and panobinostat in a thalamic syngeneic murine DMG model is feasible and safe. Neuro-Oncology, 24(Supplement_1), i174–i174. https://doi.org/10.1093/neuonc/noac079.647

Brat, D. J., Aldape, K., Bridge, J. A., Canoll, P., Colman, H., Hameed, M. R., Harris, B. T., Hattab, E. M., Huse, J. T., Jenkins, R. B., Lopez-Terrada, D. H., McDonald, W. C., Rodriguez, F. J., Souter, L. H., Colasacco, C., Thomas, N. E., Yount, M. H., van den Bent, M. J., & Perry, A. (2022). Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. Archives of Pathology & Laboratory Medicine, 146(5), 547–574. https://doi.org/10.5858/arpa.2021-0295-cp

Wei, K., Liang, Y., Yang, B., Liu, L., Cao, W., Li, T., & Wang, R. (2022). An observational MRI study of methotrexate-treated children with acute lymphoblastic leukemia in remission and subtle cognitive decline. Quantitative Imaging in Medicine and Surgery, 12(4), 2474–2486. https://doi.org/10.21037/qims-21-748

Mohile, N. A., Messersmith, H., Gatson, N. T. N., Hottinger, A. F., Lassman, A. B., Morton, J., Ney, D., Nghiemphu, P. L., Olar, A., Olson, J., Perry, J., Portnow, J., Schiff, D., Shannon, A., Shih, H. A., Strowd, R., van den Bent, M., Ziu, M., & Blakeley, J. (2021). Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. Neuro-Oncology, 24(3), 358–383. https://doi.org/10.1093/neuonc/noab279

Roytman, M., Kim, S., Glynn, S., Thomas, C., Lin, E., Feltus, W., Magge, R. S., Liechty, B., Schwartz, T. H., Ramakrishna, R., Karakatsanis, N. A., Pannullo, S. C., Osborne, J. R., Knisely, J. P. S., & Ivanidze, J. (2022). PET/MR Imaging of Somatostatin Receptor Expression and Tumor Vascularity in Meningioma: Implications for Pathophysiology and Tumor Outcomes. Frontiers in Oncology, 11. https://doi.org/10.3389/fonc.2021.820287

Sen, A., Prager, B. C., Zhong, C., Park, D., Zhu, Z., Gimple, R. C., Wu, Q., Bernatchez, J. A., Beck, S., Clark, A. E., Siqueira-Neto, J. L., Rich, J. N., & McVicker, G. (2021). Leveraging Allele-Specific Expression for Therapeutic Response Gene Discovery in Glioblastoma. Cancer Research, 82(3), 377–390. https://doi.org/10.1158/0008-5472.can-21-0810

Halatsch, M.-E., Dwucet, A., Schmidt, C. J., Mühlnickel, J., Heiland, T., Zeiler, K., Siegelin, M. D., Kast, R. E., & Karpel-Massler, G. (2021). In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma. Pharmaceuticals, 14(12), 1241. https://doi.org/10.3390/ph14121241

Dwucet, A., Pruss, M., Cao, Q., Tanriover, M., Prabhu, V. V., Allen, J. E., Peraud, A., Westhoff, M.-A., Siegelin, M. D., Wirtz, C. R., & Karpel-Massler, G. (2021). ONC201/TIC10 Is Empowered by 2-Deoxyglucose and Causes Metabolic Reprogramming in Medulloblastoma Cells in Vitro Independent of C-Myc Expression. Frontiers in Cell and Developmental Biology, 9. https://doi.org/10.3389/fcell.2021.734699

Nguyen, T. T. T., Shang, E., Shu, C., Kim, S., Mela, A., Humala, N., Mahajan, A., Yang, H. W., Akman, H. O., Quinzii, C. M., Zhang, G., Westhoff, M.-A., Karpel-Massler, G., Bruce, J. N., Canoll, P., & Siegelin, M. D. (2021). Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma. Nature Communications, 12(1). https://doi.org/10.1038/s41467-021-25501-x

Agopyan-Miu, A. H. C. W., Banu, M. A., Miller, M. L., Troy, C., Hargus, G., Canoll, P., Wang, T. J. C., Feldstein, N., Haggiagi, A., & McKhann, G. M. (2021). Synchronous supratentorial and infratentorial oligodendrogliomas with incongruous IDH1 mutations, a case report. Acta Neuropathologica Communications, 9(1). https://doi.org/10.1186/s40478-021-01265-9

Damuka, N., Macauley, S. L., Orr, M. E., Shively, C. A., Lockhart, S. N., Bansode, A., Frye, B. M., Mintz, A., Kim, J., Register, T. C., Whitlow, C. T., Craft, S., & Solingapuram Sai, K. K. (2021). Initial biological evaluation of a novel microtubule‐based PET ligand in rodent and NHP models of AD. Alzheimer’s & Dementia, 17(S4). Portico. https://doi.org/10.1002/alz.052101

Kenchappa, R. S., Liu, Y., Argenziano, M. G., Banu, M. A., Mladek, A. C., West, R., Luu, A., Quiñones-Hinojosa, A., Hambardzumyan, D., Justilien, V., Leitges, M., Sarkaria, J. N., Sims, P. A., Canoll, P., Murray, N. R., Fields, A. P., & Rosenfeld, S. S. (2021). Protein kinase Cι and SRC signaling define reciprocally related subgroups of glioblastoma with distinct therapeutic vulnerabilities. Cell Reports, 37(8), 110054. https://doi.org/10.1016/j.celrep.2021.110054

Lue, J. K., Ma, H., Marchi, E., Spivack, J. H., & O’Connor, O. A. (2021). Peripheral T-Cell Lymphoma Involvement of the Central Nervous System: Impact of Novel Therapeutics on Clinical Outcomes. Blood, 138(Supplement 1), 2469–2469. https://doi.org/10.1182/blood-2021-144933